🇺🇸 FDA
Patent

US 8404810

Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma

granted A61KA61K38/00

Quick answer

US patent 8404810 (Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma) held by Five Prime Therapeutics, Inc. expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Five Prime Therapeutics, Inc.
Grant date
Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K38/00